Antipsychotic Use Among Intellectually Disabled Individuals With Rare Genetic Variants That Confer Risk for Schizophrenia
Journal of Intellectual Disability Research · 2025
DOI: 10.1111/jir.70065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Intellectual Disability Research, 2025. Verfasst von Mark Ainsley Colijn. Beteiligte Einrichtung: Department of Psychiatry, Hotchkiss Brain Institute, Mathison Centre for Mental Health Research and Education, University of Calgary, Calgary, Albert…. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents, Intellectual Disability, Psychotic Disorders. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Rare genetic variation can predispose individuals to the development of schizophrenia, with certain genes and copy number variants (CNVs) conferring risk at the exome/genome‐wide level. Despite this strong association, little is known about antipsychotic effectiveness and tolerability among individuals with most of these disorders. As such, this retrospective chart review sought to gather more data regarding the real‐world use of antipsychotics in this context.
Methods
This largely descriptive, cross‐sectional and retrospective chart review took place at a developmental disabilities mental health clinic. Clinical information was primarily derived from electronic medical records. Individuals with a history of psychosis and antipsychotic exposure identified as having a genetic variant known to confer exome/genome‐wide risk for schizophrenia were included in the study.
Results
Of the 1196 charts reviewed, 24 individuals with a relevant genetic variant were identified, 11 of whom had experienced psychotic symptoms that were treated with antipsychotic medication. Six have 22q11.2 deletion syndrome, two have 15q11‐q13 duplication syndrome and one individual each has a 16p11.2 duplication, a 7q11.23 duplication and a missense variant in TRIO . Overall, antipsychotic therapy tended to be reasonably effective and well tolerated (particularly among those individuals who do not have 22q11.2 deletion syndrome), despite side effects of some kind occurring in most cases.
Conclusion
While this study had numerous limitations that prevent firm conclusions from being drawn, it provides preliminary evidence that antipsychotics may be relatively safe and effective in at least some of the genetic disorders most strongly associated with schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Hotchkiss Brain Institute, Mathison Centre for Mental Health Research and Education, University of Calgary, Calgary, Alberta, Canada.
ORCID-Profile: Mark Ainsley Colijn
Zitieren
APA
Colijn, M. A. (2025). Antipsychotic Use Among Intellectually Disabled Individuals With Rare Genetic Variants That Confer Risk for Schizophrenia. Journal of Intellectual Disability Research. https://doi.org/10.1111/jir.70065
Vancouver
Colijn MA. Antipsychotic Use Among Intellectually Disabled Individuals With Rare Genetic Variants That Confer Risk for Schizophrenia. Journal of Intellectual Disability Research. 2025. doi:10.1111/jir.70065
BibTeX
@article{Colijn2025,
author = {Colijn, Mark Ainsley},
title = {Antipsychotic Use Among Intellectually Disabled Individuals With Rare Genetic Variants That Confer Risk for Schizophrenia},
journal = {Journal of Intellectual Disability Research},
year = {2025},
doi = {10.1111/jir.70065}
}
EUVIMED